The FDA Has Accepted Rocket Pharmaceuticals' Biologics License Application And Granted Priority Review For RP-L201 Gene Therapy For Severe Leukocyte Adhesion Deficiency-I, With A PDUFA Date Of March 31, 2024
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted Rocket Pharmaceuticals' Biologics License Application and granted priority review for RP-L201 gene therapy for severe leukocyte adhesion deficiency-I. The PDUFA date is set for March 31, 2024.
October 02, 2023 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rocket Pharmaceuticals' RP-L201 gene therapy has been granted priority review by the FDA, potentially accelerating its market entry.
The FDA's acceptance of Rocket Pharmaceuticals' Biologics License Application and granting of priority review for its RP-L201 gene therapy is a significant regulatory milestone. This could potentially accelerate the therapy's market entry, positively impacting Rocket Pharmaceuticals' stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100